{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:38:07Z","timestamp":1773801487390,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ejphar.2012.08.017","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T14:31:43Z","timestamp":1346769103000},"page":"57-61","source":"Crossref","is-referenced-by-count":7,"title":["In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride"],"prefix":"10.1016","volume":"695","author":[{"given":"Kaoru","family":"Nakao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Momen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Umeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2012.08.017_bib1","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1248\/cpb.52.670","article-title":"Syntheses of potential metabolites of a potent \u03ba-opioid receptor agonist, TRK-820","volume":"52","author":"Kawamura","year":"2004","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2012.08.017_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2012.08.017_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-2999(94)00780-B","article-title":"Scratching behavior induced by pruritogenic but not algesiogenic agents in mice","volume":"275","author":"Kuraishi","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.08.017_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1248\/cpb.46.366","article-title":"Discovery of a structurally novel opioid \u03ba-agonist derived from 4,5-epoxymorphinan","volume":"46","author":"Nagase","year":"1998","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2012.08.017_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1358\/dot.2009.45.5.1377595","article-title":"Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients","volume":"45","author":"Nakao","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejphar.2012.08.017_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1254\/fpj.135.205","article-title":"Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch\u00ae capsules 2.5\u03bcg), a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients","volume":"135","author":"Nakao","year":"2010","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.ejphar.2012.08.017_bib7","first-page":"75","article-title":"Effect of TRK-820, a selective \u03ba-opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis","volume":"28","author":"Nakao","year":"2008","journal-title":"Jpn. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2012.08.017_bib8","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/0024-3205(87)90431-0","article-title":"Morphine-6-glucuronide, a potent mu agonist","volume":"41","author":"Pasternak","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2012.08.017_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-3565(25)20832-1","article-title":"Pharmacological characterization of mophine-6\u03b2-glucuronide, a very potent morphine metabolite","volume":"251","author":"Paul","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2012.08.017_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00265969","article-title":"Plasma levels of morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration","volume":"38","author":"Peterson","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.08.017_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0014-2999(99)00369-6","article-title":"Pharmacological properties of TRK-820 on cloned \u03bc-, \u03b4- and \u03ba-opioid receptors and nociceptin receptor","volume":"376","author":"Seki","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.08.017_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0014-2999(01)01588-6","article-title":"Antipruritic activity of the \u03ba-opioid receptor agonist, TRK-820","volume":"435","author":"Togashi","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.08.017_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2003.08.007","article-title":"Involvement of central \u03bc-opioid system in the scratching behavior in mice, and the suppression of it by the activation of \u03ba-opioid system","volume":"477","author":"Umeuchi","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.08.017_bib14","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1681\/ASN.2005020152","article-title":"\u03ba-Opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies","volume":"16","author":"Wikstr\u00f6m","year":"2005","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912007285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912007285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T21:05:37Z","timestamp":1744059937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299912007285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":14,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0014299912007285"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2012.08.017","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}